Brief Report: Factors Associated With the Selection of Initial Antiretroviral Therapy From 2009 to 2012 by Saag, Michael S. et al.
Factors associated with the selection of initial antiretroviral 
therapy from 2009 to 2012
Michael S. Saag, MD1, Andrew O. Westfall, MS2, Stephen R. Cole, PhD3, W. Christopher 
Mathews, MD, MSPH4, Daniel R Drozd, MD5, Kenneth H Mayer, MD6, Greer A. Burkholder, 
MD1, Mari Kitahata, MD, MPH5, Eric M. Maiese, PhD7, and for the CFAR Network of 
Integrated Clinical Systems (CNICS)
1Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL
2Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL
3Department of Epidemiology, University of North Carolina, Chapel Hill, NC
4Owen Clinic, University of California, San Diego, San Diego, CA
5Division of Allergy & Infectious Diseases, University of Washington, Seattle, WA
6Fenway Health Clinic, Harvard Medical School, Boston, MA
7Merck Sharp & Dohme Corp., Kenilworth, NJ USA at the time the study was conducted
Abstract
We examined factors associated with selection of initial antiretroviral regimen in the CNICS 
cohort. Patients initiating antiretroviral therapy (ART) between July 2009 and Dec 2012 were 
classified as receiving an NNRTI, boosted-PI, or raltegravir-based regimen. Among 873 patients 
initiating ART, 488 regimens contained an NNRTI, 319 a boosted-PI, and 66 raltegravir. Patients 
with depression and women were less likely to receive an NNRTI, while those with underlying 
cardiovascular disease, liver disease, and those co-infected with hepatitis C were more likely to 
receive raltegravir. Those with baseline viral load > 100,000 c/ml and those with substance use 
were more likely to receive a boosted PI. Thus, in the ‘real world’ ARV regimen choices appear to 
take into account adverse effects and patient baseline characteristics. Factors that impact initial 
regimen selection will likely become more heterogeneous over time as more choices for HIV 
therapy become available.
Introduction
Over the last decade, antiretroviral (ARV) regimens have become more effective and better 
tolerated. As a result HIV disease has changed from a near-certain death sentence to a 
chronic manageable condition (1). Treatment regimens have also become more simplified, 
with several drugs being co-formulated into single tablet regimens that can be administered 
once daily. As a result of these therapeutic advancements, there are a number of regimen 
options for use in first line therapy for patients with HIV infection (2).
Clinical trials have characterized the relative efficacy and side effect profiles for available 
treatment regimens. Clinicians typically choose a regimen to use as initial therapy for a 
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given patient based on the patient’s clinical presentation, including co-morbid conditions, 
interactions with other medications prescribed, and a regimen’s side effect profile. There are 
few existing studies regarding clinician selection of regimens in ‘real world’ clinical practice 
during the integrase inhibitor era (3).
We examined factors associated with choice of the class of initial ARV regimen in the 
CNICS cohort at eight clinical sites throughout the United States. We sought to characterize 
the distribution of initial antiretroviral treatment (ART) regimens and clinical factors 
associated with selection of one type of regimen versus others among patients initiating ART 
in the modern treatment era.
Methods
Study Patients
The CFAR Network of Integrated Clinical Systems (CNICS) cohort includes >30,000 HIV-
infected adults in care from 1995 to the present at eight HIV clinics at academic centers in 
the US, including the University of Alabama at Birmingham, University of Washington, 
University of California, San Francisco, University of California, San Diego, Case Western 
Reserve University, Harvard University / Fenway, Johns Hopkins University, and the 
University of North Carolina (4). Institutional review boards at each university have 
approved study protocols. All adult patients (> 18 years of age) initiating their first 3 (or 
more) drug regimen between July 2009 and December 2012 were included. Patients were 
excluded if they had documentation of receiving any ART (including use of one or two drug 
regimens), a viral load <200 c/ml any time prior to enrollment, had no viral load or CD4 
count value within 12 months of study entry, or participated in a clinical trial for their initial 
antiretroviral therapy.
Data
The CNICS data repository integrates comprehensive clinical data that include demographic, 
medication, laboratory, and diagnosis information collected through point-of-care electronic 
medical records (EMR) and other institutional data systems at each site. Data quality 
assessment is conducted at the sites prior to data transmission and at the time of submission 
to the CNICS Data Management Core (DMC) at the University of Washington. After 
integration into the central repository, data undergo extensive quality assurance procedures 
and data issues are reported to CNICS sites to investigate and correct. Data are updated by 
each site, fully reviewed, and integrated into the repository quarterly. We examined baseline 
factors including demographic characteristics, risk factors for HIV transmission, type of 
ART, diagnoses (including AIDS-defining illnesses (ADIs), mental health and substance use 
disorders, hepatitis B and C virus infection, liver disease, diabetes mellitus, hypertension, 
cardiovascular and cerebrovascular disease, CD4 counts and viral load.
Statistical Analysis
We examined the association between baseline demographic characteristics and comorbid 
conditions diagnosed prior to initiation of a patient’s first ARV regimen classified into three 
categories: NNRTI, boosted-PI (PI/r), and raltegravir-based, which was the only integrase 
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strand transfer inhibitor available for use in practice during the study period. The nucleoside/
tide backbone component of the regimen was not evaluated. Factors suspected of being 
associated with regimen choice were explored using polytomous (multinomial) logistic 
regression models. All models included site as a stratification factor.
Results
Baseline characteristics of the 873 study patients at the time of ART initiation are shown in 
Table 1. The majority of patients were male (82%), most of whom (73%) had sex with men, 
between the 19 and 47 years of age (78%), Caucasian (56%), non-Hispanic (81%), non-
IVDU (86%), and had public insurance (56%). The median viral load was 33,283 c/ml and 
median CD4 count was 351 cells/ul. Thirty four percent of patients had a diagnosis of 
depression, 33% had a substance use disorder, 26% had a psychiatric disorder other than 
depression, 16% had a diagnosis of liver disease / hepatitis C, 15% had a diagnosis of 
hypertension, 11% had a prior AIDS-defining illness, 5% had a diagnosis of diabetes, and 
2% had a diagnosis of cardio-cerebrovascular disease.
Initial antiretroviral regimens were NNRTI-based (n=488; 56%), PI-based (n=319; 36%), or 
raltegravir-based (n=66; 8%) regimens. Multivariable models were fit. Of note, some 
variables were not included in the multivariable model because they either were not 
significant in univariate analyses (p > 0.3), had a significant degree of missing data, and/or 
there were concerns about collinearity. The variables not included were Hispanic ethnicity, 
baseline CD4 value, psychiatric or related disorder, history of an opportunistic infection, and 
presence of diabetes. In multivariable models, there was no significant difference in 
selection of NNRTI, PI, or raltegravir-based regimens based on age, race, risk factor, or 
diagnosis of hypertension (see Table 2). In contrast, individuals with higher viral load at 
baseline (> 100,000 c/ml) were more likely to receive a PI-based regimen than an NNRTI-
based one (OR 1.8, 95% CI 1.3–2.5) as were women (OR 2.5, 95% CI 1.5–4.3). Those 
subjects with a history of depression were much more likely to start a raltegravir-based 
regimen than either an NNRTI (OR 3.5, 95% CI 1.9–6.4) or a PI-based regimen (OR 2.5, 
95% CI 1.3–5.0). Similarly, patients with a diagnosis of HCV or liver disease were more 
likely to receive a raltegravir-based regimen (OR 3.3, 95% CI 1.4–7.8) than NNRTI-based 
one, although we found no significant selection preference for raltegravir over a PI-based 
regimen (OR 1.9, 95% CI 0.9–4.2). Those subjects with a diagnosis of cardiovascular or 
cerebrovascular disease were more likely to receive a raltegravir-based regimen than either 
an NNRTI (OR 4.7, 95% CI 1.3–17.0) or PI-based regimen (OR 4.9, 95% CI 1.2–19.2). 
Patients who reported active substance use were more likely to receive a PI-based regimen 
than an NNRTI (OR 1.7, 95% CI 1.2–2.5) or raltegravir-based regimen (OR 0.3, 95% CI 
0.1–0.7).
Discussion
The remarkable advances in antiretroviral therapy have led to the development of a number 
of highly effective regimens available for clinicians to choose as initial treatment for their 
patients (5). Most of the regimens developed over the last decade have similar efficacy in 
clinical trials, but differ in their side effect profiles and potential for drug-drug interactions 
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(6–15). Clinical trial entry criteria often exclude patients who are not considered good 
candidates for some of the regimens used in the study, however in clinical practice clinicians 
select a regimen best suited for a particular patient. This study evaluated how antiretroviral 
agents are used in “real-world” clinical practice and types of regimens initiated among 
patients with different baseline laboratory or co-morbid conditions.
NNRTI-based regimens were the initial treatment in over half of the patients in our study. 
Although the most commonly employed regimen, we did not find demographic, laboratory, 
or co-morbid factors that favored selection of an NNRTI-based regimen over the other two 
regimen categories. In contrast, the use of PI-based or raltegravir-based regimens was 
selected over NNRTI-based regimens in the context of specific clinical scenarios. Taken 
together, NNRTI-based regimens seemed to be the ‘default’ regimen with clinicians opting 
for other regimens as indicated by the patient’s clinical presentation, likely due to co-
formulation of efavirenz as the only single pill once daily regimen available during the time 
period of this study. This thesis is supported by prior reports that demonstrated high-uptake 
by efavirenz-based regimens, in particular, from 2000–2009 (16). By the end of the study 
period (2007) in the study by Willig, et al, over 80% of subjects were taking an efavirenz-
based regimen (17).
A PI-based or raltegravir-based regimen was more likely to be selected than an NNRTI-
based regimen among women, those who had a history of substance abuse, and those with 
higher viral load, liver disease, depression, cardiovascular disease, hepatitis C / liver disease, 
or a higher number of co-morbid conditions. More specifically, both raltegravir and PI-based 
regimens were more likely to be selected for women and patients with a number of co-
morbid conditions in keeping with the relative contraindication of the use of efavirenz 
among women of child-bearing potential (during the time of the study) and the complexities 
of managing co-morbid conditions. Similarly, raltegravir-based regimens were preferred 
over both NNRTI- and PI-based regimens for those with depression or underlying 
cardiovascular disease. Likely due to an association between depression and the use of 
efavirenz, potential toxicity of nevirapine-based regimens in those with HCV or liver disease 
(6, 14) as well as potential drug-drug interactions for boosted PI regimens (15). In contrast, 
PI use was preferred over use of NNRTI regimens for those who had higher (> 100,000 
c/ml) viral load values at baseline and preferred over both NNRTI- and raltegravir-based 
regimens for those patients with a history of substance abuse likely due to concerns 
regarding adherence and a higher barrier to resistance associated with PI-based therapies.
Our study has limitations. The number of patients studied limits the ability to detect 
differences. Although the time period evaluated (July 2009 – December 2012) represents 
fairly modern use of antiretroviral therapy, several newer therapies have been introduced 
over the last 2 years, in particular, two additional integrase inhibitor agents, elvitegravir and 
dolutegravir (7–9), which would require additional follow-up time to evaluate. The exclusion 
of patients who participated in clinical trials may have resulted in inclusion of individuals 
who had more co-morbidities or conditions that would not have allowed them to enter the 
clinical trial; however, the exclusion of these patients enables greater focus of real-world 
clinical practice where treatment is not driven by study protocol. This study focused on the 
‘anchor’ drug of the regimen and did not examine patterns of use with regard to the 
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nucleoside/tide backbone. The majority of patients in the study were using tenofovir-based 
regimens and our ability to examine differences was limited by sample size. Future studies 
should address the impact of the newer integrase inhibitors and the role of nucleoside/tide 
backbone selection in combination with the anchor drugs of the regimen. Finally, our study 
cannot dissect the role patient preference plays in the selection of regimens (18).
To our knowledge, this study is the first to evaluate exclusively initial ART regimen 
selection by providers in a ‘real-world’ practice setting. The findings demonstrate that ARV 
regimen choices take into account adverse effects and patient baseline characteristics. As 
more choices for HIV therapy become available, factors that impact initial regimen selection 
will likely become more heterogeneous over time including drug-drug interaction 
considerations when treating patients co-infected with HCV, those with underlying kidney 
disease, and cost of therapy as more generic drug formulations become available.
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Table 2
Multivariable polytomous regression model with site as stratification factor
Raltegravir vs.
NNRTI
Raltegravir vs. PI PI/r vs. NNRTI
19–36 years old 1.00 1.00 1.00
37–47 years old 1.13 (0.58,2.22) 1.66 (0.83,3.34) 0.83 (0.58,1.20)
48–75 years old 0.74 (0.33,1.65) 1.11 (0.48,2.61) 0.84 (0.56,1.27)
White race 1.00 1.00 1.00
Black race 0.66 (0.33,1.31) 0.70 (0.34,1.47) 0.91 (0.61,1.37)
Other/unknown race 0.44 (0.13,1.52) 0.54 (0.15,1.86) 0.85 (0.49,1.47)
Male 1.00 1.00 1.00
Female 1.69 (0.71,3.99) 0.55 (0.21,1.42) 2.53 (1.50,4.25)
Heterosexual 1.00 1.00 1.00
IVDU 0.78 (0.25,2.39) 0.88 (0.31,2.53) 0.89 (0.49,1.62)
MSM 0.98 (0.43,2.26) 0.86 (0.34,2.16) 0.90 (0.56,1.45)
Baseline VL ≤100,000 1.00 1.00 1.00
Baseline VL >100,000 1.75 (0.92,3.34) 0.71 (0.36,1.41) 1.77 (1.26,2.48)
HCV+ or Liver Disease 3.33 (1.42,7.79) 1.91 (0.86,4.23) 1.36 (0.84,2.19)
Depression 3.48 (1.90,6.36) 2.54 (1.28,5.03) 1.34 (0.96,1.89)
Substance Use 0.62 (0.30,1.29) 0.31 (0.14,0.68) 1.73 (1.19,2.51)
Cardiovascular/Cerebrovascular 4.70 (1.30,17.04) 4.86 (1.23,19.17) 1.16 (0.36,3.70)
Hypertension 1.62 (0.76,3.45) 1.26 (0.58,2.73) 1.33 (0.84,2.11)
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